Integrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E320-E334

  Soejima, Yurie ^a,c   Inoue, Masafumi ^b   Takahashi, Yoshihisa ^a   Uozaki, Hiroshi ^a   Sawabe, Motoji ^c   Fukusato, Toshio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Cholangiolocellular carcinoma; Hepatocellular carcinoma; Integrin; Laminin; Stem cell features

Indexed keywords

ALPHAVBETA6 INTEGRIN; FIBRONECTIN; ITGB6 PROTEIN; LAMININ; MESSENGER RNA; SCLEROPROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 6;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CELL DIFFERENTIATION; CHOLANGIOLOCELLULAR CARCINOMA; DIAGNOSTIC VALUE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UPREGULATION;

EID: 84918586280     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12312     Document Type: Article

References (38)

1. Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer 1959; 12: 753-759.
2. Liver Cancer Study Group of Japan, ed. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd English edn. Tokyo: Kanehara & Co., LtD, 2010.
3. Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System, 4th edn. Lyon: International Agency for Research on Cnacer (IARC), 2010; 225-227.
4. Komuta M, Spee B, Vander Borght S etal. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-1556.
5. Sempoux C, Fan C, Singh P etal. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 2011; 31: 104-110.
6. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339: 269-280.
7. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011; 23: 607-614.
8. Labat-Robert J. Cell-Matrix interactions, the role of fibronectin and integrins. A survey. Pathol Biol (Paris) 2012; 60: 15-19.
9. Baker EL, Zaman MH. The biomechanical integrin. J Biomech 2010; 43: 38-44.
10. Volpes R, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 1993; 142: 1483-1492.
11. Couvelard A, Bringuier AF, Dauge MC etal. Expression of integrins during liver organogenesis in humans. Hepatology 1998; 27: 839-847.
12. Shiojiri N, Sugiyama Y. Immunolocalization of extracellular matrix components and integrins during mouse liver development. Hepatology 2004; 40: 346-355.
13. Nejjari M, Couvelard A, Mosnier JF etal. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol 2001; 195: 473-481.
14. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
15. Missan DS, DiPersio M. Integrin control of tumor invasion. Crit Rev Eukaryot Gene Expr 2012; 22: 309-324.
16. Thomas GJ, Nystrom ML, Marshall JF. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006; 35: 1-10.
17. Al-Hazmi N, Thomas GJ, Speight PM, Whawell SA. The 120kDa cell-binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing cells by increasing matrix metalloproteinase-2 and -9 secretion. Eur J Oral Sci 2007; 115: 454-458.
18. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008; 135: 660-670.
19. Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009; 10: 645-652.
20. Liu S, Liang B, Gao H etal. Integrin alphavbeta6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma. Head Neck Oncol 2013; 5: 7.
21. Patsenker E, Wilkens L, Banz V etal. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 2010; 52: 362-369.
22. Volpes R, van den Oord JJ, Desmet VJ. Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology 1991; 101: 200-206.
23. Giannelli G, Astigiano S, Antonaci S etal. Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis 2002; 19: 217-223.
24. Giancotti FG. Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci 2007; 28: 506-511.
25. Beaulieu JF. Integrin alpha6beta4 in colorectal cancer. World J Gastrointest Pathophysiol 2010; 1: 3-11.
26. Ding YB, Deng B, Huang YS etal. A high level of integrin alpha6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype. Dig Dis Sci 2013; 58: 1627-1635.
27. Murakami T, Yano H, Maruiwa M, Sugihara S, Kojiro M. Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice. Hepatology 1987; 7: 551-556.
28. Yano H, Iemura A, Haramaki M etal. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol 1996; 24: 413-422.
29. Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T. Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma. Hepatol Res 2013; 43: 959-969.
30. Shiota K, Taguchi J, Nakashima O, Nakashima M, Kojiro M. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep 2001; 8: 263-268.
31. Iwahashi S, Utsunomiya T, Shimada M etal. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today 2013; 43: 654-660.
32. Brafman DA, Phung C, Kumar N, Willert K. Regulation of endodermal differentiation of human embryonic stem cells through integrin-ECM interactions. Cell Death Differ 2013; 20: 369-381.
33. Chaturvedi P, Singh AP, Moniaux N etal. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 2007; 5: 309-320.
34. Nejjari M, Hafdi Z, Gouysse G etal. Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: an in vivo and in vitro study. Hepatology 2002; 36: 418-426.
35. Torbenson M, Wang J, Choti M etal. Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 2002; 15: 826-830.
36. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003; 200: 465-470.
37. Aishima S, Matsuura S, Terashi T etal. Aberrant expression of laminin gamma 2 chain and its prognostic significance in intrahepatic cholangiocarcinoma according to growth morphology. Mod Pathol 2004; 17: 938-945.
38. Tanimizu N, Kikkawa Y, Mitaka T, Miyajima A. alpha1- and alpha5-containing laminins regulate the development of bile ducts via beta1 integrin signals. J Biol Chem 2012; 287: 28586-28597.